Video
Post hoc analysis investigates enzalutamide plus androgen deprivation therapy in men with oligometastatic prostate cancer
Author(s):
“The good news for patients is that the survival and radiographic progression-free survival [were] substantially improved in all subsets,” says Andrew J. Armstrong, MD, MSc.
Video Player is loading.
In this video, Andrew J. Armstrong, MD, MSc, discusses the background and findings of the study, “The efficacy of enzalutamide (Enza) plus androgen deprivation therapy (ADT) on oligometastatic hormone-sensitive prostate cancer: extended post hoc analysis of ARCHES,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Armstrong is a professor of medicine, surgery, and pharmacology and cancer biology at Duke University and a member of the Duke Cancer in Durham, North Carolina.
Related Videos
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
Related Content
